Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial (POSTPOD)

This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.

Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.

Study Overview

• Status: Recruiting
• Conditions: Gestational Diabetes Mellitus in Pregnancy
• Intervention / Treatment: Device: Continuous Glucose Monistor

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Dana Levin-Lopez, MPH; Phone Number: 310-794-8893; Email: dlevinlopez@mednet.ucla.edu
• Study Contact Backup: Name: Rujuta Sathe; Phone Number: 310-794-8893; Email: RSathe@mednet.ucla.edu

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90095
      • Recruiting
      • University of California, Los Angeles
      • Contact: Dana Levin-Lopez, MPH; Phone Number: 310-794-8893; Email: dlevinlopez@mednet.ucla.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Prenatal care at UCLA Health
• Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
• Confirmed gestational diabetes diagnosis based on 2-step approach
• Maternal age >= 18 years

Exclusion Criteria:

• Pre-gestational diabetes (T1DM or T2DM)
• Multifetal gestation
• Intra-amniotic infection by clinical criteria
• Postpartum hemorrhage
• Maternal ICU admission
• Known allergy to medical-grade adhesive
• Presence of skin lesions at anticipated CGM application site
• Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
• Metformin use
• Steroid use
• Terbutaline use within 4 hours of delivery
• Cystic fibrosis
• MODY (mature onset of diabetes in the young)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Continuous Glucose Monitor; Administration of a Continuous Glucose Monitor within 2 hours after delivery for 24-hour collection of glycemic data.	Device: Continuous Glucose Monistor; Continuous glucose monitoring sensor that provides 24/7 detailed glycemic information. Participants will wear for 24 hours and then be instructed to peel off.; Other Names: Dexcom G7

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test	Regression analysis to assess strength and direction of the relationship between postpartum CGM data and 2 hr GTT	24 hours postpartum and 1-3 months postpartum
Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum	Regression analysis to assess strength and direction of the relationship between postpartum CGM data and HbA1c	24 hours postpartum and 1-3 months postpartum

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient satisfaction with CGM use immediately postpartum to evaluate long term risk	Patient satisfaction will be measured via survey response on following statements using 5 point likert scale; Applying the CGM was painless.; Applying the CGM was easy.; Wearing the CGM for 24 hours postpartum was painless.; Wearing the CGM for 24 hours postpartum was easy.; Wearing the CGM did not interfere with my activities of daily living.; Wearing the CGM did not cause any side effects.; Removing the CGM was painless.; Removing the CGM was easy.; If given a choice between the 1-3 month postpartum OGTT and wearing the CGM for 24 hours immediately postpartum, I would choose wearing the CGM.	1-3 months postpartum after glucose tolerance test, 12-24 months postpartum after A1C blood test

Collaborators and Investigators

• Sponsor: University of California, Los Angeles
• Investigators: Principal Investigator: Christina Han, MD, University of California, Los Angeles

Study record dates

Study Major Dates

• Study Start (Actual): September 28, 2025
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): June 1, 2030

Study Registration Dates

• First Submitted: December 18, 2025
• First Submitted That Met QC Criteria: February 26, 2026
• First Posted (Actual): March 4, 2026

Study Record Updates

• Last Update Posted (Actual): March 4, 2026
• Last Update Submitted That Met QC Criteria: February 26, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 25-0020

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes